KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $1.91 $2.71 Friday, 26th Apr 2024 CANF stock ended at $1.98. This is 3.13% more than the trading day before Thursday, 25th Apr 2024. During the day the stock fluctuated 4.71% from a day low at $1.91 to a day high of $2.00.
90 days $1.91 $2.71
52 weeks $1.71 $3.33

Historical Can-Fite BioPharma Ltd prices

Date Open High Low Close Volume
Apr 11, 2016 $3.45 $3.59 $3.22 $3.35 2 752 800
Apr 08, 2016 $3.00 $3.15 $2.91 $3.10 129 100
Apr 07, 2016 $3.05 $3.11 $2.92 $3.05 194 200
Apr 06, 2016 $2.80 $3.25 $2.77 $3.11 792 400
Apr 05, 2016 $2.83 $2.89 $2.71 $2.79 168 100
Apr 04, 2016 $2.73 $3.00 $2.70 $2.73 237 900
Apr 01, 2016 $2.83 $2.84 $2.67 $2.77 109 900
Mar 31, 2016 $2.71 $2.80 $2.71 $2.79 40 000
Mar 30, 2016 $2.69 $2.75 $2.58 $2.71 68 900
Mar 29, 2016 $2.65 $2.79 $2.63 $2.72 82 900
Mar 28, 2016 $2.88 $2.92 $2.65 $2.74 160 600
Mar 24, 2016 $2.69 $2.93 $2.55 $2.93 207 500
Mar 23, 2016 $2.77 $3.10 $2.55 $2.69 588 100
Mar 22, 2016 $2.38 $2.85 $2.38 $2.70 637 100
Mar 21, 2016 $2.32 $2.45 $2.32 $2.38 168 200
Mar 18, 2016 $2.33 $2.41 $2.27 $2.38 67 100
Mar 17, 2016 $2.45 $2.45 $2.32 $2.37 183 000
Mar 16, 2016 $2.27 $2.37 $2.23 $2.34 62 300
Mar 15, 2016 $2.33 $2.39 $2.25 $2.31 59 500
Mar 14, 2016 $2.35 $2.40 $2.27 $2.37 148 700
Mar 11, 2016 $2.29 $2.36 $2.22 $2.28 57 800
Mar 10, 2016 $2.24 $2.28 $2.11 $2.20 65 200
Mar 09, 2016 $2.37 $2.38 $2.21 $2.28 85 500
Mar 08, 2016 $2.58 $2.58 $2.27 $2.33 78 900
Mar 07, 2016 $2.48 $2.53 $2.39 $2.42 101 900
Click to get the best stock tips daily for free!

About Can-Fite BioPharma Ltd

Can-Fite BioPharma Ltd Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical tria... CANF Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT